ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus

This publication has 51 references indexed in Scilit:

• PPARγ-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin
  Hypertension, 2005
• Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes
  The American Journal of Cardiology, 2005
• Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease
  New England Journal of Medicine, 2004
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
  American Heart Journal, 2004
• Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
  Hypertension, 2004
• Ramipril treatment suppresses islet fibrosis in Otsuka Long–Evans Tokushima fatty rats
  Biochemical and Biophysical Research Communications, 2004
• Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
  Drugs, 2004
• Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
  Hypertension, 2003
• Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension
  Hypertension, 2003
• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002